Search results
Results from the WOW.Com Content Network
The approval of this new medication can help alleviate the stigma associated with postpartum depression, Hillary Ammon, a clinical psychologist at the Center for Anxiety & Women's Emotional ...
The US Food and Drug Administration has approved the medication zuranolone for the treatment of major depressive disorder and severe postpartum depression – making it the first FDA-approved oral ...
Sep. 7—A new drug treating postpartum depression was approved earlier this month by the Food and Drug Administration — possibly filling a gap in care, depending on the drug's accessibility to ...
Her doctors refused to prescribe brexanolone, the only FDA-approved medication specifically for postpartum depression at the time. “No woman should suffer like I did after having a child ...
Zuranolone was approved by the US Food and Drug Administration (FDA) for the treatment of postpartum depression in August 2023. [6] [13] The FDA granted the application for zuranolone priority review and fast track designations. [6] Approval of Zurzuvae was granted to Sage Therapeutics, Inc. [6]
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
A much-awaited treatment for postpartum depression, zuranolone, hit the market in December, promising an accessible and fast-acting medication for a debilitating illness. But most private health ...
The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder (MDD), or clinical depression, as well as postpartum depression, which affect millions of people.